help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Itskovitz-Eldor, J.
Right arrow Articles by Sealey, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Itskovitz-Eldor, J.
Right arrow Articles by Sealey, J. E.
The Journal of Clinical Endocrinology & Metabolism Vol. 82, No. 2 461-464
Copyright © 1997 by The Endocrine Society


Reproductive Endocrinology

Ovarian Origin of Plasma and Peritoneal Fluid Prorenin in Early Pregnancy and in Patients with Ovarian Hyperstimulation Syndrome1

Joseph Itskovitz-Eldor, Shahar Kol, Nathan Lewit and Jean E. Sealey

Department of Obstetrics and Gynecology (J.I-E., S.K., N.L.), Rambam Medical Center and Technion-Israel Institute of Technology, Faculty of Medicine, Haifa 31096, Israel; Cardiovascular Center (J.E.S.), The New York Hospital—Cornell University Medical College, New York, New York 10021

Address correspondence and reprint requests to: Joseph Itskovitz-Eldor M.D., D.Sc., Department of Obstetrics and Gynecology, Rambam Medical Center, Haifa 31096 Israel.

Prorenin is the major product of renin gene expression in the ovary. Plasma levels of prorenin are elevated in ovarian-stimulated patients and during early pregnancy. To further elucidate the source of the elevated plasma levels of prorenin, we measured prorenin, renin activity, angiotensinogen, and steroid hormone levels in the plasma, luteal fluids (luteal cysts), ascitic fluid, and in ovarian venous samples collected from a patient with severe ovarian hyperstimulation syndrome (OHSS) and ectopic pregnancy. Prorenin/renin was also measured in plasma and in peritoneal fluid obtained during therapeutic paracentesis from four patients with OHSS.

Several corpora luteal fluids were obtained that were rich in estradiol (E2) and progesterone (P). Ovarian venous E2 and P were 20-fold higher than in arterial blood and as high or higher than the levels detected in the luteal fluids. The ratios of the hormonal levels in ascitic fluid and plasma were 1.9 for P and 1.4 for E2. A wide range of prorenin concentrations [1279 ± 918 SD ng/mL/hr, n = 6] were found in corpora luteal fluids, but in each the prorenin concentration was higher than in plasma (494 ng/mL/hr). Prorenin but not renin was higher (+23%) in ovarian venous than arterial blood. Prorenin in the 7 liters of ascitic fluid aspirated (2686 ng/mL/hr) was 5-fold higher than in plasma and similar to the levels measured in the corpora lutea with the highest prorenin concentrations. Renin in luteal cysts and ascitic fluid constituted 3% and 6% of the total renin (renin + prorenin), respectively. Total renin was also higher in peritoneal fluid (1538 ± 925 ng/mL/hr) than in plasma (375 ± 237 ng/mL/hr) of the 4 additional patients with severe OHSS.

These findings indicate that the ovary secretes prorenin during early pregnancy and that its secretion is directed preferentially from the luteal cysts into the peritoneal cavity. In light of recent evidence of an effect of prorenin on the vascular system, the presence of a huge reservoir of prorenin in the peritoneal cavity of patients with OHSS suggests a potential role for prorenin in the pathogenesis of this syndrome.




This article has been cited by other articles:


Home page
Hum ReprodHome page
E. Pau, I. Alonso-Muriel, R. Gomez, E. Novella, A. Ruiz, J. A. Garcia-Velasco, C. Simon, and A. Pellicer
Plasma levels of soluble vascular endothelial growth factor receptor-1 may determine the onset of early and late ovarian hyperstimulation syndrome
Hum. Reprod., June 1, 2006; 21(6): 1453 - 1460.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
R. Gomez, C. Simon, J. Remohi, and A. Pellicer
Administration of Moderate and High Doses of Gonadotropins to Female Rats Increases Ovarian Vascular Endothelial Growth Factor (VEGF) and VEGF Receptor-2 Expression that Is Associated to Vascular Hyperpermeability
Biol Reprod, June 1, 2003; 68(6): 2164 - 2171.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
R. Gomez, C. Simon, J. Remohi, and A. Pellicer
Vascular Endothelial Growth Factor Receptor-2 Activation Induces Vascular Permeability in Hyperstimulated Rats, and this Effect Is Prevented by Receptor Blockade
Endocrinology, November 1, 2002; 143(11): 4339 - 4348.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
M. Ludwig, W. Jelkmann, O. Bauer, and K. Diedrich
Prediction of severe ovarian hyperstimulation syndrome by free serum vascular endothelial growth factor concentration on the day of human chorionic gonadotrophin administration
Hum. Reprod., October 1, 1999; 14(10): 2437 - 2441.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1997 by The Endocrine Society